CAS 116424-69-2: (2R,3S,3aS,7S,7aR)-2-(1,3-Benzodioxol-5-yl)-3,3a,7,7a-tetrahydro-3a,4-dimethoxy-3-methyl-7-(2-propen-1-yl)-6(2H)-benzofuranone

Fargesone A is a synthetic corticosteroid, which is derived from chemical synthesis processes involving glucocorticoid analogs. It exerts its effects through the modulation of gene expression, primarily by binding to glucocorticoid receptors within cells, resulting in both transactivation and transrepression. This interaction leads to alterations in the transcription of anti-inflammatory and immunosuppressive genes, effectively reducing inflammatory responses. The principal applications of Fargesone A are focused on research and experimental settings, where it is used to study the mechanisms of inflammation, immune system modulation, and cell signaling pathways. Its potent anti-inflammatory properties make it a valuable tool in elucidating the role of glucocorticoids in various physiological and pathological processes, including autoimmune disorders, allergic reactions, and other inflammatory conditions. However, due to its synthetic nature and specific mode of action, Fargesone A is typically confined to laboratory research rather than clinical therapeutic use. It offers insights into potential therapeutic targets and mechanisms for the development of new treatments for inflammatory diseases.

Fargesone A inhibits NO production in LPS/interferon-gamma-stimulated J774.1 murine macrophages.